Abstracts must be submitted online. Complete instructions for submission can be found in the submission portal. The deadline to submit an abstract is Tuesday, July 30, 2026 at 11:59 pm, ART. No exceptions will be made.

Submission length is limited to 2,500 characters.

Characters in the abstract title, body and table/image caption will be counted (including spaces). Characters in the author and institution listing will not be counted. There is a strict limit of one graph, figure or table to each submitted abstract. No exceptions will be made.

• Abstracts that have been presented or have been accepted to present at an SRS Annual Meeting or IMAST may not be considered for submission to this meeting.
• Any paper accepted and presented at this meeting can be submitted for SRS Annual Meeting after a two-year follow-up.
  • These papers will be reviewed as an original paper. They will not be considered follow-ups. 

The Scoliosis Research Society (SRS) must ensure balance, independence, objectivity, and scientific rigor in all educational activities. Therefore, as a person who is in position to influence or control the content of a CME activity, ALL abstract authors must disclose all financial relationships held in the past 24 months with ineligible companies.* If the financial relationship has occurred in the past 24 months, but has since ended, we still require you to disclose the relationship.

Visit this link to disclose
The username is the email associated with your abstract and the password your first name

*An ineligible company is an entity whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services consumed by or on patients. For specific examples of ineligible companies visit accme.org/standards.

SRS strongly prefers that pharmaceuticals and proprietary software/databases as well as surgical approaches or specific instrumentation such as “Surgimap, MIMICS, EOS Imaging, ROTEM, , XLIF, DLIF, AxiaLIF, Solera, Vertex, Expedium, Mountaineer, Shilla, VEPTR etc.,” are not used in presentations. These terms should be replaced by a generic term or description of the drug, software/database and/or instrumentation or technique unless the use of the term directly impacts learners’ understanding of the presentation or data. Instrumentation may also be referred to when the device name is a landmark system that is no longer sold (i.e. Harrington, Cotrel-Dubousset, Luque). It is recognized that studies evaluating a device or devices or comparing different devices or techniques may require the use of product or technique names. If a device trade name or industry developed technique using a trademarked name are used in an abstract or presentation, it will be specifically reviewed by the CME Committee for evaluation of any relevant financial relationships. When there is a known relevant financial relationship, expanded verbal disclosure will be necessary at the time of presentation. Furthermore, if a product name is mentioned, the audience should be informed of why it is necessary to give the name.

Please view the SRS Product Translation Glossary for more information.

All submitted abstracts will undergo a blinded review. To maintain an unbiased review of all abstracts, please do NOT include any identifying information such as researcher, institution, or study group names in your abstract. Inclusion of any identifying information will disqualify your abstract from review.

One-Year Follow Up Requirement
One-year clinical follow-up is required for abstract submission. The one-year follow-up rule does not apply to categories of basic science or biomechanical studies or for topics where one-year follow-up is irrelevant, such as 30-day readmission rates.

By submitting an abstract to the Regional Scientific Meeting, abstract authors agree that at least one (1) author will attend the meeting for which the abstract is accepted and will be available to present on the date and at the time assigned by the organizing committees. Authors will be notified of presentation times at the time of or shortly after notification of acceptance and are expected to make appropriate travel arrangements to ensure that at least one of the abstract’s authors will be in attendance. In addition, presenting authors are expected to register to attend the meetings for which they are accepted by the deadline set forth in their acceptance notification. Abstracts for which an author is not pre-registered by the dates set forth may be withdrawn from the program.

Presentations must be given in English

The Presenting author must be from the regions of Latin America.

All selected authors will be required to respond to a formal invitation by December 1, 2026, to confirm participation in the program.

This meeting will be for the region, by the region. Therefore, a submitted abstract must have a senior author and/or presenting author and a majority of the authors from the region of Latin America.

Authors unable to present their paper in person should inform SRS as soon as possible with a co-author that can attend to present the paper. If no one is able to attend in person, please inform SRS by December 15, 2026, so an alternate paper can be substituted. Please note that in the case of a "no-show" podium presentation, the presenting author associated with the "no-show" paper will be prohibited from presenting any papers at the next two Annual Meetings.

Authors unable to present their paper or participate in-person should inform SRS as soon as possible with a co-author that can attend to present the paper. If no one can attend in-person, please inform SRS by October 30, 2026, so an alternate paper can be substituted.

Please Note: In the case of a “no-show” podium presentation, the presenting author associated with the “no-show” paper will be prohibited from presenting any papers at the next two meetings.